Page 7 - இணையான வாயு போவர்ட் வாகனங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இணையான வாயு போவர்ட் வாகனங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இணையான வாயு போவர்ட் வாகனங்கள் Today - Breaking & Trending Today

Fortuna Silver Mines Inc.: Fortuna reports 2020 full year production of 11.3 million silver equivalent ounces and issues 2021 guidance


Fortuna Silver Mines Inc.: Fortuna reports 2020 full year production of 11.3 million silver equivalent ounces and issues 2021 guidance
Fortuna Silver Mines Inc.
(NYSE: FSM) (TSX: FVI) reports production results for the fourth quarter and full year 2020 from its three operating mines in Latin America, the San Jose Mine in Mexico, the Caylloma Mine in Peru, and the Lindero Mine in Argentina. For the full year 2020, the Company produced 7,133,717 ounces of silver and 55,349 ounces of gold or 11.3 million silver equivalent
1 ounces. The Company withdrew its production and cost guidance for 2020 in early April due to the COVID-19 pandemic and the temporary shutdown of operations mandated by governments in Mexico and Argentina (refer to Fortuna news release dated April 2, 2020 (https://www.fortunasilver.com/site/assets/files/5217/2020-04-02-fvi-nr.pdf)). Due to the uncertainties related to the impact caused by COVID-19 constraints on Fortuna s business and operations, the C ....

Province Of British Columbia , British Columbia , United States , United Kingdom , Trinidad And Tobago , San Cristobal , Edwin Gutierrez , Jorgea Ganoza , Carlos Baca , Geoff Allard , Denys Parra Murrugarra , Amri Sinuhaji , Eric Chapman , National Instrument , Global Laboratory In Mendoza , Technical Services , International Financial Reporting Standards , Company Annual Information Form , Planning For The Company , Fortuna Silver Mines Inc , Association Of Professional Engineers , Global Laboratory , Silver Mines , Latin America , San Jose Mine , Caylloma Mine ,

The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive


The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group. ....

Rafael Ba , Rajiv Jalan , Amber Fennell , Banwari Agarwal , Universitario Gregorio Mara , Nathan Davies , Akaza Bioscience , Zenios Bioscience , Kostenloser Wertpapierhandel , Luniversidad Complutense , University College London , European Union Horizon , School Of Medicine , Liver Failure Group , Yaqrit Ltd , Consilium Strategic Communications , Professor Rajiv Jalan , Professor Nathan Davies , Founding Member , Consultant Intensivist , Royal Free Hospital , Chief Investigator , Chronic Liver Failure , Hospital General Universitario Gregorio Mara , European Union , Takeda Pharmaceutical ,

Carbalive: The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis


(2)
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation
The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis
Planning for pivotal trials to support approval in Europe is now under way
7
th January, 2021 - The
CARBALIVE Consortium( CARBALIVE or the Consortium ) is pleased to announce positive data from the Phase 2 equivalent randomised, double-blind clinical trial of Carbalive, a product candidate for the treatment of patients with decompensated cirrhosis. Carbalive is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeabilit ....

Rajiv Jalan , Amber Fennell , Universitario Ram , Agustin Albillos , Akaza Bioscience , Zenios Bioscience , Jane Macnaughtan , Kostenloser Wertpapierhandel , University College London , European Union Horizon , Liver Failure Group At University College London , Cajal Institute For Health , Digestive Diseases Group , Carbalive Consortium , Consilium Strategic Communications , European Foundation , Chronic Liver Failure , European Union , Professor Rajiv Jalan , Liver Failure Group , Founding Member , Project Coordinator , Hospital Universitario Ram , Universidad De Alcal , Cajal Institute , Takeda Pharmaceutical ,